We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis has signed an agreement to divest the US rights to its Proleukin (aldesleukin) medicine to UK-based Clinigen Group for a total cash consideration of up to $210m.....